Navigation Links
Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress
Date:7/10/2009

of Antiplatelet Therapy

ADP-Mediated Aggregation as a Pharmacodynamic Assay Underestimates the Antithrombotic Activity of Elinogrel, a Competitive, Reversible P2Y12 Inhibitor, Relative to Clopidogrel (Presentation #PP-TH-027)

    Presenter:  Pamela Conley
    Date: Thursday, July 16, 12:30-2:15 p.m.  
    Location:  Poster Area, Platelet Biology

Clopidogrel and Prasugrel Prolong Primary Hemostasis in the Mouse Beyond Levels Associated with P2Y12 Inhibition (Presentation #AS-TH-022) 

    Presenter:  Patrick Andre
    Date: Thursday, July 16, 2:15-3:45 p.m.       
    Location:  157 ABC Oral, Platelets as Drug Targets

Reconstructed Recombinant Factor Xa as an Antidote to Reverse Anticoagulation by Factor Xa Inhibitors (Presentation #OC-TH-107) 

    Presenter:  Genmin Lu
    Date: Thursday, July 16, 4:00-5:00 p.m.
    Location:  102 AB Oral, Inhibitors of Coagulation and Fibrinolysis

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concepts that are designed to provide significant advances over current treatments for cardiovascular disease, inflammatory disease and cancer. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1B in upfront and milestone payments plus escalating double-digit royalties on future sales. Betrixaban, its oral Factor Xa inhibitor is licensed to Merck & Co., Inc., and elinogrel, its P2Y(12) ADP receptor antagonist and potential competitor for Plavix* (clopidogrel), is licensed to Novartis. Both betrixaban and elinogrel are Phase II product candidates that have best-in-class features to address the global multi-billion hospital, specialty, and chronic care anticoagulant and antiplatelet markets,
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Portola Pharmaceuticals to Host Conference Call at 11:00 a.m. Eastern Time Tomorrow to Discuss Betrixaban Partnership and Provide Corporate Update
2. Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
3. Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)
4. MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration
5. Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
6. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
7. Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
8. Arena Pharmaceuticals Announces Public Offering of Common Stock
9. Solvay Pharmaceuticals, Inc. Announces Commercial Availability of CREON(R) (Pancrelipase) Delayed-Release Capsules
10. Jazz Pharmaceuticals Pays Accrued Interest Under Senior Secured Notes
11. Jazz Pharmaceuticals Completes $7 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... people from around the world have visited Israel,s Dead ... a reputation that dates back over 2000 years, and ... the introduction of two bath salt lines from SaltWorks ... of Dead Sea salt in their own homes. ,, ... salt and essential oils - but no artificial colors ...
(Date:12/16/2009)... Americans have myopia now than in the ,70s, study ... (nearsightedness) is more common in the United States than ... Eye Institute study shows. , Researchers compared National Health ... white participants from 1971 to 1972 and from 8,339 ... participants were 12 to 54 years old. , The ...
(Date:12/16/2009)... visitors can earn a free 21-count one week trial bottle sample ... ... MI (PRWEB) December 16, 2009 -- ImmuneResponse247.com announces ... Sample” of Immune Response 247™ 6 Mushroom Formula , with ... Immune Response 247™ 6 Mushroom Formula is packaged in FDA approved ...
(Date:12/16/2009)... presented with the Weatherhead 100 Upstart Award on December 3, 2009. ... Ohio and is a testament to hard work, commitment, innovation and ... ... (PRWEB) December 16, 2009 -- Request A Test, Ltd. is proud ... December 3, 2009. The Weatherhead 100 showcases the fastest growing ...
(Date:12/16/2009)... be the perfect gift to give that special woman who has ... Licensed Esthetician Mary Schook introduces exceptional beauty products online while educating ... , ... (PRWEB) December 16, 2009 -- The holidays are ... that special woman who has everything? Why stem cells, of course!, ...
Breaking Medicine News(10 mins):Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 2Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 3Health News:Free Sample of Proven Health Mushroom Supplement Offered By ImmuneResponse247.com 4Health News:Request A Test Receives Weatherhead 100 Upstart Award 2Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2
... today,that its annual long-term care insurance training event will ... "This is THE long-term care ... training from the nation,s leading LTCI sales trainer -- ... Marketing. "The,primary focus of this seminar is for ...
... 27 Interleukin Genetics, Inc. (NYSE Alternext US: ILI) today announced ... Alternext US LLC (the "Exchange") that outlines the Company,s strategy ... The Company expects the Exchange to formally respond to the ... the Company may be able to continue its listing up ...
... University of Texas at San Antonio (UTSA) has received ... Engineering has been awarded a $199,884, 24-month grant by ... , "This is one of the first grants we ... and energy efficiency," said Efstathios Michaelides, mechanical engineering professor, ...
... Provides Blueprint for Renewing RelationshipsNEW YORK, Jan. 27 ... relationships on the rocks, nothing says, "I love you" ... seasoned couples therapist and educator Marty Babits, LCSW, BCD, ... that arise in any relationship. "We,ve learned over the ...
... Dr. Barry Friedberg developed the ultra-safe, ultra-comfortable ... successfully educating the public and fellow anesthesiologists about ... Congressional award for PK anesthesia,s great safety and ... Afghanistan. Benefits: Patients don,t experience nausea, vomiting or ...
... fabrication offerings to include products for use in hospitals. Midbrook will ... surgical tools, and carts for use in the medical environment. , ... ... a custom sheet metal fabrication house over 30 years ago. They are ...
Other Medicine News:Health News:Phyllis Shelton's LTCI Sales Skills Seminar a Must-Attend Event for Insurance Professionals 2Health News:Interleukin Genetics' Submits Plan to Regain Compliance with Continued Listing Standards 2Health News:UTSA receives federal funding for fossil fuel research 2Health News:Breakthrough Rx for Relationships Offers Hope 2Health News:Cosmetic Surgery - PK 'Goldilocks' Anesthesia: All of the Benefits, None of the Risks 2Health News:Midbrook Now Offers Custom Metal Fabrication for Hospitals 2
(Date:12/16/2009)... 16 , ... Microplasmin Recruits a Total of Over,640 patients ... ThromboGenics NV (Euronext Brussels: THR), a ... of innovative treatments for eye,disease, vascular disease ... completed,the enrolment of the second Phase III ...
(Date:12/15/2009)... Inc. (Nasdaq: BLUD ), a global leader in ... today announced that it will release its fiscal 2010 ... the market close. The Company will host a conference ... (Eastern Time) to discuss the results. ,, ... by dialing 1-888-324-9321 (Passcode: BLUD). Investors can also access ...
(Date:12/15/2009)... -- Robbins & Myers, Inc. (NYSE: RBN ... its fiscal 2010 first quarter ending November 30, 2009, ... A live webcast is scheduled for ... Peter C. Wallace, President and Chief Executive Officer, ... Officer, will be discussing the Company,s performance and responding ...
Breaking Medicine Technology:ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4Aware Software and Development Services Enable State of the Art Fingerprint Card Scanning 10015 1Aware Software and Development Services Enable State of the Art Fingerprint Card Scanning 10015 2Aware Software and Development Services Enable State of the Art Fingerprint Card Scanning 10015 345 000 excess deaths annually linked to lack of health insurance 3A Harvard study 57890 145 000 excess deaths annually linked to lack of health insurance 3A Harvard study 57890 2Researchers prolong the plasma half life of biopharmaceutical proteins 14192 1Researchers prolong the plasma half life of biopharmaceutical proteins 14192 2
... series facilitates fast and effective resection of ... shaped meniscal rim. The flat, crescent-shaped tip ... even the tightest joint spaces. Made in ... years of engineering experience in arthroscopy hand ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... ratchet design provides fingertip ratchet disengagement allowing ... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ...
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
Medicine Products: